Mediwound reports fourth quarter and full year 2024 financial results and provides corporate update

Initiated value, a global phase iii pivotal trial of escharex® for venous leg ulcers expanded strategic research collaborations with industry leaders, now including kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of year-end 2024 conference call today, march 19 at 8:30am eastern time yavne, israel, march 19, 2025 (globe newswire) -- mediwound ltd. (nasdaq: mdwd), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended december 31, 2024, and provided a corporate update.
MDWD Ratings Summary
MDWD Quant Ranking